Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06414915
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-05-10
Brief Title:
Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation
Sponsor:
National Cancer Center China
Organization:
National Cancer Center China
Study Overview
Official Title:
A Single-arm Open Single-center Prospective and Exploratory Clinical Study of Surufatinib Combined With Tislelizumab in the Treatment of Advanced Lung Cancer With Neuroendocrine Differentiation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Currently there are no standard treatment and relevant exploration for NSCLC patients with NED The study aims to explore the efficacy and safety of surufatinib combined with tislelizumab in the treatment of NSCLC with NED in order to provide a new treatment option for NSCLC patients with NED
Detailed Description:
This is a single-arm open single-center prospective and exploratory clinical study We planned to enroll 29 patients who would receive surufatinib plus tislelizumab until disease progression intolerance or withdrawal of consent The study aims to explore the efficacy and safety of surufatinib combined with tislelizumab in the treatment of NSCLC with NED in order to provide a new treatment option for NSCLC patients with NED
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None